BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Applied Imaging Corp. (AICX.OB) Stockholders Approve Acquisition By Genetix Group plc (GTX.L)


11/22/2006 10:33:23 AM

SAN JOSE, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Applied Imaging Corporation ("Applied Imaging" or "the Company") , a leading supplier of automated imaging and image analysis systems, today announced that stockholders have approved the Company's acquisition by Genetix Group plc. ("Genetix") (AIM: GTX), the United Kingdom-based cell biology, proteomics, and genomics health technology group. The all-cash transaction is valued at $25.8 million, with Genetix paying $4.20 per share to acquire all of Applied Imaging's common stock. Aquilo Partners, Inc. acted as exclusive financial advisor to Applied Imaging in the transaction.

"We are pleased that our stockholders have approved this transaction," said Robin Stracey, Applied Imaging's President and CEO. "Not only do we believe this is the right path for our stockholders, but it also strengthens our overall competitive position and enhances our ability to fully capitalize on the products and technologies that we have developed. We look forward to working closely with the Genetix team in leveraging the collective capabilities of both organizations to bring greater value to our customers."

About Applied Imaging

Applied Imaging Corp., based in San Jose, California, is a leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and cancer applications. The Company markets a wide range of imaging and image analysis systems for fluorescence and brightfield microscopy, including the Company's Ariol(R) and CytoVision(R) product families. Applied Imaging has installed over 4,000 systems in over 1,000 laboratories in more than 60 countries. The Company is also developing a system for the detection, quantification and characterization of circulating tumor cells from the blood of cancer patients. More information about Applied Imaging can be found at http://www.aicorp.com.

About Genetix

Genetix adds value to scientists working at the cutting edge of cell biology, proteomics and genomics through its pioneering development of automated systems. The Company's core skill is in the design, development and manufacture of innovative systems that reduce the time and cost of introducing new biopharmaceuticals. Its products include instruments and consumables that were used in the Human Genome Project and are now used in the genetic analysis of human diseases -- analysing and selecting cells for the production of therapeutic proteins. Genetix has established a broad and strong customer base among many of the world's leading biotech and pharmaceutical companies & research institutions. Genetix is quoted on AIM (symbol GTX) and is based in New Milton, Hampshire, UK, with offices in the United States and Germany.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, regarding, among other matters, the expected potential of the proposed transaction. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Actual results could differ materially from those projected in the forward-looking statements as a result of the terms and conditions specified in the definitive merger agreement. The forward-looking statements in this news release are made as of November 21, 2006, and Applied Imaging is under no obligation to revise or update these forward-looking statements.

Contacts: CCG Investor Relations Applied Imaging Corp. Crocker Coulson, President Terry Griffin, Chief Financial Officer 10960 Wilshire Boulevard 120 Baytech Drive Suite 2050 San Jose, CA 95134 Los Angeles, CA 90024 408-719-5417 310-477-9800 tgriffin@aicorp.comCrocker.Coulson@ccgir.com

Applied Imaging Corporation

CONTACT: Crocker Coulson, President of CCG Investor Relations,+1-310-477-9800, Crocker.Coulson@ccgir.com; or Terry Griffin, ChiefFinancial Officer of Applied Imaging Corp., +1-408-719-5417,tgriffin@aicorp.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES